Question

H2N+ 01 a New VIUIUgICal lalget huy compound 3. Cholecystokinin C-terminal tetrapeptide (CCK-4) is the smallest (molecular weight 596.7, CLog P=-2.1) active form of CCK found in the brain. Release of CCK in the brain is believed to promote anxiety. (a) What would be possible concerns with using CCK-4 as a lead compound for an orally active antianxiety drug? (b) Name some alternative approaches to identifying a lead compound. 8. a.

3. Cholecystokinin C-terminal tetrapeptide (CCK-4) is the smallest (molecular weight 596.7, CLog P=-2.1) active form of CCK found in the brain. Release of CCK in the brain is believed to promote anxiety. (a) What would be possible concerns with using CCK-4 as a lead compound for an orally active antianxiety drug? (b) Name some alternative approaches to identifying a lead compound.

answer Q 3

Answer 1

SOLUTION COKU a pephide fragment desured from hormone cliolecystokinin. larger peptide It ack-primarily in brain as an anxiogenic. It causes devence anxiety symptoms when administered to humans even in love doses and is induced in scientific research to induce panic attacks for purpose of testing new anxiolytic drugs. =|| Ot has shalt duration of action and rapidly breaks down I once inside the body. b) - Alternative appowach is to use phenotypic Svreening to identify disease relevant targets. A screntist used phage - display antibody library to isolate human monoclonal antibodies that bind to the surface of tumowe cells. clones are individually screened by immunograininge the antigens recognized by those cloner mere isolated by immunoprecipitation d identified by mass spectroscopy.